Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000950170-24-140566
Filing Date
2024-12-26
Accepted
2024-12-26 18:19:45
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 15010
2 EX-99.17 ck0000888721-ex99_17.pdf EX-99.17 58955
  Complete submission text file 0000950170-24-140566.txt   98208
Mailing Address 3 ROCK ROAD SANDYFORD INDUSTRIAL ESTATES DUBLIN IRELAND L2 18
Business Address IDA BUSINESS PARK, BRAY, CO WICKLOW IRELAND DUBLIN IRELAND L2 18 01135312955111
TRINITY BIOTECH PLC (Subject) CIK: 0000888721 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-44122 | Film No.: 241581943
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address #11-B-05, 11F, 20, GUKJEGEUMYUNG-RO YEONGDEUNGPO-GU SEOUL M5 07326
Business Address #11-B-05, 11F, 20, GUKJEGEUMYUNG-RO YEONGDEUNGPO-GU SEOUL M5 07326 (512) 650-6322
New Main Equity Co., Ltd. (Filed by) CIK: 0002049455 (see all company filings)

EIN.: 000000000 | State of Incorp.: M5 | Fiscal Year End: 1231
Type: SCHEDULE 13D